Back to Search
PAMELA MUNSTER, MD
MD
Hematology & Oncology Physician
NPI: 1619997145IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
C53203(CA)
Medical Oncology Physician
Internal Medicine — Medical Oncology
Code: 207RX0202X
ME85618(FL)
Education
OTHER
Class of 1989
Research & Publications (20)
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
PMID 19318486·Clin Cancer Res·2009
3-trial
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
PMID 17317835·Clin Cancer Res·2007
3-trial
Arzoxifene: the development and clinical outcome of an ideal SERM.
PMID 16503767·Expert Opin Investig Drugs·2006
6-review
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
PMID 11731433·Cancer Res·2001
8-other
Predictive factor for the response to adjuvant therapy with emphasis in breast cancer.
PMID 11737886·Breast Cancer Res·2001
6-review
Cognitive functioning in breast cancer survivors: a controlled comparison.
PMID 19224550·Cancer·2009
4-observational
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
PMID 19185986·Cancer Lett·2009
6-review
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
PMID 19318484·Clin Cancer Res·2009
3-trial
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
PMID 19434004·Melanoma Res·2009
8-other
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
PMID 19372552·Mol Cancer Ther·2009
8-other
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
PMID 19351752·Clin Cancer Res·2009
3-trial
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
PMID 19318485·Clin Cancer Res·2009
3-trial
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
PMID 19029422·J Clin Oncol·2008
3-trial
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
PMID 18823053·Cancer·2008
3-trial
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
PMID 17805538·Cancer Chemother Pharmacol·2008
3-trial
Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory.
PMID 18495413·J Pain Symptom Manage·2008
8-other
Exploring the differential experience of breast cancer treatment-related symptoms: a cluster analytic approach.
PMID 18043948·Support Care Cancer·2008
8-other
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
PMID 17908979·Clin Cancer Res·2007
3-trial
Discussion of fertility preservation with newly diagnosed patients: oncologists' views.
PMID 18648955·J Cancer Surviv·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1825 4TH ST
SAN FRANCISCO, CA 94143 - Phone
- (415) 885-3631
Quick Facts
- NPI
- 1619997145
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile